Eric Storvick, MD
Internal Medicine · Mankato, MNNPI 1841279833
Payments from drug & device makers
Across 56 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$262
- Travere Therapeutics, Inc.$83
- Amgen$58
- AstraZeneca$58
- Bayer$51
- Dexcom, Inc.$47
- plus $622 from 31 others
What the payments were for
- Speaking & faculty fees$25021%
- Food & beverage$93279%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 2 | $262 |
| Travere Therapeutics, Inc. | 2 | $83 |
| Amgen(2 entities) | 4 | $58 |
| AstraZeneca | 3 | $58 |
| Bayer | 3 | $51 |
| Dexcom, Inc. | 3 | $47 |
| Abbott | 2 | $42 |
| Abiomed | 1 | $40 |
| Daiichi Sankyo Inc. | 2 | $38 |
| GSK | 2 | $30 |
| Aurinia Pharma U.S., Inc. | 2 | $30 |
| Novartis | 2 | $29 |
| Grifols USA, LLC | 2 | $25 |
| Sanofi | 2 | $25 |
| Philips North America LLC | 2 | $24 |
| Boehringer Ingelheim | 1 | $23 |
| Electromed, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| Soleno Therapeutics, Inc. | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $15 |
| Surgenex LLC | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Ardelyx, Inc. | 1 | $13 |
| Harmony Biosciences LLC | 1 | $12 |
| Melinta Therapeutics, LLC | 1 | $11 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,182 in reported general payments places this provider in the 90th percentile of 1,924 internal medicine providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 118 | $139,187 |
| OzempicSemaglutide | 92 | $119,798 |
| MounjaroTirzepatide | 43 | $55,319 |
| FarxigaDapagliflozin Propanediol | 45 | $52,831 |
| JardianceEmpagliflozin | 34 | $38,563 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 13 | $32,680 |
| TrulicityDulaglutide | 25 | $31,084 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 133 | $27,413 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 32 | $25,950 |
| XareltoRivaroxaban | 27 | $25,122 |
| Humalog Kwikpen U-100Insulin Lispro | 56 | $22,739 |
| RybelsusSemaglutide | 13 | $20,981 |
| CreonLipase/Protease/Amylase | 15 | $15,256 |
| JanuviaSitagliptin Phosphate | 15 | $15,256 |
| BelsomraSuvorexant | 24 | $10,880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $58 | $52,83145 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $23 | $46,96149 claims |
| Johnson & JohnsonXarelto | $16 | $25,12227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,924 internal medicine providers in Minnesota.
Other internal medicine in Mankato
- Sandeep KhosaMankato$6K
- Eusebio Emmanuel FerrerApple Valley$10.7M
- Dylan ZyllaSaint Louis Park$4M
- Shannon DoyleMaplewood$3.2M
- Robert PignoloRochester$2M
- Thomas MartensBrooklyn Center$1.3M
- Gregory PolandRochester$494K
- Patricia WalkerSaint Paul$356K
- Beth ThielenMinneapolis$343K
- Bruce JohnsonSt. Paul$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.